Use of Granix (tbo-filgrastim) for Patients Receiving Chemotherapy for B-cell Lymphoma

Rationale for G-CSF Use in B-cell Lymphoma

Granulocyte colony-stimulating factors (G-CSFs) like tbo-filgrastim are recommended for patients receiving chemotherapy with ≥20% risk of developing febrile neutropenia (FN) 1, 2
G-CSFs significantly reduce the risk of FN, hospitalization, and potentially infection-related mortality in patients receiving myelosuppressive chemotherapy 2

Tbo-filgrastim (Granix) is specifically approved for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies (including B-cell lymphoma) receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of FN 1, 3
The American Society of Clinical Oncology (ASCO) guidelines explicitly state that pegfilgrastim, filgrastim, tbo-filgrastim, and filgrastim-sndz can all be used for prevention of treatment-related FN 1, 3

Initial dose of 5 mcg/kg/day administered subcutaneously 4, 5
Start 24-72 hours after completion of chemotherapy (not on the same day as chemotherapy) 5
Continue until post-nadir absolute neutrophil count recovery to normal or near-normal levels by laboratory standards 5

Primary prophylaxis with G-CSFs is strongly recommended for patients with chemotherapy regimens associated with ≥20% risk of FN 1, 2

Common adverse effects of G-CSFs include bone pain, which can be managed with nonsteroidal anti-inflammatory drugs 2
Avoid concurrent administration of G-CSFs with chemotherapy on the same day 5

A single injection of pegfilgrastim per chemotherapy cycle provides similar neutrophil support to daily injections of filgrastim or tbo-filgrastim, but the choice between agents should be based on convenience, cost, and clinical situation 1
For patients receiving weekly chemotherapy regimens, daily G-CSFs like tbo-filgrastim may be more appropriate than long-acting formulations 4, 5